Renovaro Biosciences (RENB) has provided an update.
Renovaro Inc. has been notified about the termination of a crucial License Agreement with Weird Science LLC, which impacts their product candidate RENB-HV-01, a genetically modified cell therapy. Although this project was already deprioritized in favor of more promising ventures like the cancer vaccine candidate RENB-DC-11, the company hasn’t acknowledged the termination as final and is exploring its options. Despite this setback, Renovaro remains active in HIV research, working on innovative treatments to enhance the immune response against the virus.
For detailed information about RENB stock, go to TipRanks’ Stock Analysis page.
